CD79B and lymphoma: Polatuzumab (32, 33), an antibody drug conjugates(ADC) antibody drug targeting CD79B, binds to the CD20 antigen, inhibiting B cell growth and proliferation in the CD79B region, and has been proven to have therapeutic effects in specific types of lymphomas, such as DLBCL and EMZL refractory or relapsed cases.